These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17671180)

  • 21. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function.
    Schebesta A; McManus S; Salvagiotto G; Delogu A; Busslinger GA; Busslinger M
    Immunity; 2007 Jul; 27(1):49-63. PubMed ID: 17658281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.
    Wang X; Li Z; Naganuma A; Ye BH
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15018-23. PubMed ID: 12407182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic gatekeeper function of B-lymphoid transcription factors.
    Chan LN; Chen Z; Braas D; Lee JW; Xiao G; Geng H; Cosgun KN; Hurtz C; Shojaee S; Cazzaniga V; Schjerven H; Ernst T; Hochhaus A; Kornblau SM; Konopleva M; Pufall MA; Cazzaniga G; Liu GJ; Milne TA; Koeffler HP; Ross TS; Sánchez-García I; Borkhardt A; Yamamoto KR; Dickins RA; Graeber TG; Müschen M
    Nature; 2017 Feb; 542(7642):479-483. PubMed ID: 28192788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.
    Cattoretti G; Pasqualucci L; Ballon G; Tam W; Nandula SV; Shen Q; Mo T; Murty VV; Dalla-Favera R
    Cancer Cell; 2005 May; 7(5):445-55. PubMed ID: 15894265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.
    Renné C; Martin-Subero JI; Eickernjäger M; Hansmann ML; Küppers R; Siebert R; Bräuninger A
    Am J Pathol; 2006 Aug; 169(2):655-64. PubMed ID: 16877363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.
    Barth TF; Barth CA; Kestler HA; Michl P; Weniger MA; Buchholz M; Möller P; Gress T
    J Pathol; 2007 Feb; 211(3):305-13. PubMed ID: 17152084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin.
    Traverse-Glehen A; Verney A; Baseggio L; Felman P; Callet-Bauchu E; Thieblemont C; Ffrench M; Magaud JP; Coiffier B; Berger F; Salles G
    Leukemia; 2007 Aug; 21(8):1821-4. PubMed ID: 17476282
    [No Abstract]   [Full Text] [Related]  

  • 28. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.
    Bertrand P; Bastard C; Maingonnat C; Jardin F; Maisonneuve C; Courel MN; Ruminy P; Picquenot JM; Tilly H
    Leukemia; 2007 Mar; 21(3):515-23. PubMed ID: 17230227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pax5--a critical inhibitor of plasma cell fate.
    Nera KP; Lassila O
    Scand J Immunol; 2006 Sep; 64(3):190-9. PubMed ID: 16918686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Locus-specific ChIP combined with NGS analysis reveals genomic regulatory regions that physically interact with the Pax5 promoter in a chicken B cell line.
    Fujita T; Kitaura F; Yuno M; Suzuki Y; Sugano S; Fujii H
    DNA Res; 2017 Oct; 24(5):537-548. PubMed ID: 28586432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.
    Wohlfart S; Sebinger D; Gruber P; Buch J; Polgar D; Krupitza G; Rosner M; Hengstschläger M; Raderer M; Chott A; Müllauer L
    Am J Pathol; 2004 Mar; 164(3):1081-9. PubMed ID: 14982861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice.
    Chen E; Kwon YT; Lim MS; Dubé ID; Hough MR
    Oncogene; 2006 Sep; 25(42):5752-63. PubMed ID: 16862188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoforms of Pax5 and co-regulation of T- and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton's lymphoma.
    Bharti B; Mishra R
    Biochim Biophys Acta; 2011 Dec; 1813(12):2071-8. PubMed ID: 21854813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAX5 and circ1857 affected DLBCL progression and B-cell proliferation through regulating GINS1.
    Wang T; Chen Z; Li C; Zhang W; Huang W; Xue J; Wang J; Li S
    Cancer Sci; 2023 Aug; 114(8):3203-3215. PubMed ID: 37221950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of two promoters for human D-amino acid oxidase gene: implication for the differential promoter regulation mediated by PAX5/PAX2.
    Tran DH; Shishido Y; Chung SP; Trinh HT; Yorita K; Sakai T; Fukui K
    J Biochem; 2015 May; 157(5):377-87. PubMed ID: 25500505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The regulation of the B-cell gene expression programme by Pax5.
    Holmes ML; Pridans C; Nutt SL
    Immunol Cell Biol; 2008 Jan; 86(1):47-53. PubMed ID: 17998914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells.
    McManus S; Ebert A; Salvagiotto G; Medvedovic J; Sun Q; Tamir I; Jaritz M; Tagoh H; Busslinger M
    EMBO J; 2011 May; 30(12):2388-404. PubMed ID: 21552207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells.
    Dong BW; Zhang WB; Qi SM; Yan CY; Gao J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2293-2300. PubMed ID: 29964012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic uses of Pax5 immunohistochemistry.
    Feldman AL; Dogan A
    Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas.
    Moretti L; Medeiros LJ; Kunkalla K; Williams MD; Singh RR; Vega F
    Mod Pathol; 2012 Feb; 25(2):231-6. PubMed ID: 22037256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.